Bausch + Lomb (NYSE:BLCO) Cut to Hold at Wall Street Zen

Bausch + Lomb (NYSE:BLCO) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms have also commented on BLCO. HC Wainwright boosted their price objective on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Stifel Nicolaus set a $16.00 price target on Bausch + Lomb in a research report on Thursday. Evercore set a $18.00 price objective on Bausch + Lomb and gave the company an “in-line” rating in a research report on Monday, January 5th. JPMorgan Chase & Co. lifted their price objective on Bausch + Lomb from $13.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $18.00 target price on shares of Bausch + Lomb in a research note on Thursday. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus price target of $18.00.

Bausch + Lomb Price Performance

Shares of BLCO stock opened at $17.95 on Friday. The business’s fifty day moving average is $17.06 and its 200 day moving average is $15.85. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.77. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of -17.60, a PEG ratio of 1.01 and a beta of 0.61. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $18.12.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.38 billion. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The business’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.25 EPS. Research analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

Several institutional investors have recently added to or reduced their stakes in BLCO. Goldman Sachs Group Inc. raised its stake in shares of Bausch + Lomb by 428.7% in the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock worth $4,345,000 after purchasing an additional 242,993 shares during the last quarter. Woodline Partners LP boosted its position in shares of Bausch + Lomb by 0.5% during the first quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after buying an additional 1,436 shares during the last quarter. Gruss & Co. LLC bought a new stake in Bausch + Lomb in the 2nd quarter worth about $130,000. Fountainhead AM LLC bought a new stake in Bausch + Lomb in the 2nd quarter worth about $193,000. Finally, Kazazian Asset Management LLC purchased a new position in Bausch + Lomb in the 2nd quarter worth about $722,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q4 revenue beat and operating leverage: Revenue of about $1.41B topped estimates and management highlighted strong revenue momentum and adjusted EBITDA expansion, supporting a constructive view on margin recovery and growth. Article Title
• Positive Sentiment: Analyst upgrade: Zacks moved BLCO to a Rank #2 (Buy), reflecting growing optimism on earnings prospects which can provide upside momentum. Article Title
• Positive Sentiment: Bullish research note: A Seeking Alpha review highlights 7% constant-currency Q4 revenue growth, 27% adjusted EBITDA growth, a product pipeline (contact lenses, dry-eye, premium IOLs) and management’s 5–7% annual revenue target through 2028 — supporting a multi-year growth story. Article Title
• Positive Sentiment: Price-target lift: Wells Fargo raised its price target to $18 (equal weight), a modest endorsement that reduces near-term downside risk. Article Title
• Neutral Sentiment: Earnings call/transcripts published — read for detail: Full Q4 earnings call transcripts are available (MSN / InsiderMonkey) for investors wanting management commentary on margins, guidance and product timing. Article Title
• Neutral Sentiment: Strategy/PR items: Management is promoting innovation (CEO highlights upcoming contact-lens innovations and has tied pay to AI literacy), which may support long-term positioning but is uncertain near-term catalyst. Article Title
• Negative Sentiment: EPS miss: Reported EPS of $0.32 missed consensus (~$0.35), which drove immediate volatility and raised short-term profitability concerns despite the revenue beat. Article Title
• Negative Sentiment: Analyst divergence and downside views: Bank of America reiterated a Sell citing structural/margin headwinds (PT $15); Stifel maintains Hold — mixed-to-negative analyst posture could cap upside. Article Title
• Negative Sentiment: Market reaction was mixed: some outlets reported an intra-session gap down tied to the earnings miss even as other coverage noted shares later edged higher — signalling investor uncertainty and possible continued volatility. Article Title

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.